DELRAY BEACH, Fla., Nov. 16, 2016 (GLOBE NEWSWIRE) — PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today that it has published a white paper and data on its successful detection of the Zika virus on its Firefly Dx polymerase chain reaction (“PCR”) breadboard prototype pathogen detection system (“prototype system”). The white paper can be found in the Research and White Papers section of PositiveID’s website or by clicking here.
PositiveID used GenArraytion Inc.’s Aedes Aegypti MultiFLEX™ PCR test, which targets four genetic regions of the Zika virus, on PositiveID’s Firefly Dx prototype system. PositiveID is developing the Firefly Dx prototype system to be a handheld, fully automated, lab quality device able to detect bio-threats at the point of need in less than 30 minutes. Currently, PCR tests are run on large lab equipment and take a minimum of four hours to deliver results. A design advantage of Firefly Dx is that it does not require additional equipment or separate steps for sample preparation and purification, unlike current lab-based equipment, thus reducing time to results as well as cost per test. In addition, there is significantly less chance of sample contamination compared to existing testing methods.
“Testing for Zika virus and other disease outbreaks quickly and cost-effectively at the point of need is critical for stopping further transmission,” stated William J. Caragol, Chairman and CEO of PositiveID. “Unfortunately, as is often the case, because lab-based testing demands both significant time and financial resources, many people are not being tested at the point of need, allowing the spread of an infection to continue.”
Zika is a fever-causing virus transmitted by the Aedes Aegypti mosquito that can cause microcephaly, a serious congenital condition in which babies are born with head and brain abnormalities, and Guillain-Barre syndrome, a rare neurological disorder that can result in paralysis.
In addition to Zika virus, the Firefly Dx prototype system has also successfully detected a number of other pathogenic organisms including Ebola, E. coli, influenza, MRSA, MSSA, C. diff and others.
About PositiveID Corporation
PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.
Statements about PositiveID’s future expectations, including the likelihood that a design advantage of Firefly Dx is that it does not require additional equipment or separate steps for sample preparation and purification, unlike current lab-based equipment, thus reducing time to results as well as cost per test; the likelihood that there is significantly less chance of sample contamination compared to existing testing methods; the likelihood that testing for Zika virus and other disease outbreaks quickly and cost-effectively at the point of need is critical for stopping further transmission; the likelihood that because lab-based testing demands both significant time and financial resources, many people are not being tested at the point of need, allowing the spread of an infection to continue; constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID’s actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to target the professional healthcare market, as well as other risks. Additional information about these and other factors that could affect the Company’s business is set forth in the Company’s various filings with the Securities and Exchange Commission, including those set forth in the Company’s 10-K filed on April 12, 2016, and 10-Qs filed on August 12, 2016, May 16, 2016, and November 12, 2015, under the caption “Risk Factors.” The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.